trending Market Intelligence /marketintelligence/en/news-insights/trending/71xBOnkLB6AL88ag433Efg2 content esgSubNav
In This List

Lonza secures long-term agreement to manufacture kidney drug

Video

S&P Capital IQ Pro | Powering Your Edge

Video

S&P Capital IQ Pro | Unrivaled Sector Coverage

Blog

Enterprises are missing out on 24B by not optimizing cloud spending not going multicloud

Blog

Investment Research Analysts Providing Greater Coverage on Inflation


Lonza secures long-term agreement to manufacture kidney drug

Lonza Group Ltd. nabbed a contract to manufacture Voclosporin on Aurinia Pharmaceuticals Inc.'s behalf.

Lonza Group will supply the patent-protected investigational drug for phase 3 clinical trial to determine whether it can be used to treat lupus nephritis, an inflammation of the kidneys.

The agreement also gives Lonza exclusivity to supply the drug for up to 20 years.